Vasopressin in hemorrhagic shock

Review article

Ravi R. Rajani, Chad G. Ball, David V. Feliciano, Gary - Vercruysse

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Trauma with resultant hypovolemic shock remains both prevalent and difficult to treat. Standard strategies using volume resuscitation and catecholamine support have historically yielded poor results. Vasopressin has emerged as a possible pharmacologic adjunct, particularly in patients with shock refractory to the administration of fluids and catecholamines. Much of the data regarding vasopressin is extrapolated from its usefulness in cases of nonhypovolemic human shock, which are supported by convincing animal studies. It is true that humans show a deficiency in vasopressin minutes after significant hemorrhage that can respond to administration of exogenous vasopressin. When given in physiological dosing regimens, vasopressin appears to be a safe adjunct to other therapy. Definite recommendations regarding indications for use, recommended dose, and long-term outcome in patients with hemorrhagic shock await a much needed prospective, randomized, controlled trial.

Original languageEnglish (US)
Pages (from-to)1207-1212
Number of pages6
JournalAmerican Surgeon
Volume75
Issue number12
StatePublished - Dec 2009
Externally publishedYes

Fingerprint

Hemorrhagic Shock
Vasopressins
Shock
Catecholamines
Neurogenic Diabetes Insipidus
Resuscitation
Randomized Controlled Trials
Hemorrhage
Wounds and Injuries
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Rajani, R. R., Ball, C. G., Feliciano, D. V., & Vercruysse, G. . (2009). Vasopressin in hemorrhagic shock: Review article. American Surgeon, 75(12), 1207-1212.

Vasopressin in hemorrhagic shock : Review article. / Rajani, Ravi R.; Ball, Chad G.; Feliciano, David V.; Vercruysse, Gary -.

In: American Surgeon, Vol. 75, No. 12, 12.2009, p. 1207-1212.

Research output: Contribution to journalArticle

Rajani, RR, Ball, CG, Feliciano, DV & Vercruysse, G 2009, 'Vasopressin in hemorrhagic shock: Review article', American Surgeon, vol. 75, no. 12, pp. 1207-1212.
Rajani RR, Ball CG, Feliciano DV, Vercruysse G. Vasopressin in hemorrhagic shock: Review article. American Surgeon. 2009 Dec;75(12):1207-1212.
Rajani, Ravi R. ; Ball, Chad G. ; Feliciano, David V. ; Vercruysse, Gary -. / Vasopressin in hemorrhagic shock : Review article. In: American Surgeon. 2009 ; Vol. 75, No. 12. pp. 1207-1212.
@article{67695ee1eeb14b59b72421d9318630b8,
title = "Vasopressin in hemorrhagic shock: Review article",
abstract = "Trauma with resultant hypovolemic shock remains both prevalent and difficult to treat. Standard strategies using volume resuscitation and catecholamine support have historically yielded poor results. Vasopressin has emerged as a possible pharmacologic adjunct, particularly in patients with shock refractory to the administration of fluids and catecholamines. Much of the data regarding vasopressin is extrapolated from its usefulness in cases of nonhypovolemic human shock, which are supported by convincing animal studies. It is true that humans show a deficiency in vasopressin minutes after significant hemorrhage that can respond to administration of exogenous vasopressin. When given in physiological dosing regimens, vasopressin appears to be a safe adjunct to other therapy. Definite recommendations regarding indications for use, recommended dose, and long-term outcome in patients with hemorrhagic shock await a much needed prospective, randomized, controlled trial.",
author = "Rajani, {Ravi R.} and Ball, {Chad G.} and Feliciano, {David V.} and Vercruysse, {Gary -}",
year = "2009",
month = "12",
language = "English (US)",
volume = "75",
pages = "1207--1212",
journal = "American Surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "12",

}

TY - JOUR

T1 - Vasopressin in hemorrhagic shock

T2 - Review article

AU - Rajani, Ravi R.

AU - Ball, Chad G.

AU - Feliciano, David V.

AU - Vercruysse, Gary -

PY - 2009/12

Y1 - 2009/12

N2 - Trauma with resultant hypovolemic shock remains both prevalent and difficult to treat. Standard strategies using volume resuscitation and catecholamine support have historically yielded poor results. Vasopressin has emerged as a possible pharmacologic adjunct, particularly in patients with shock refractory to the administration of fluids and catecholamines. Much of the data regarding vasopressin is extrapolated from its usefulness in cases of nonhypovolemic human shock, which are supported by convincing animal studies. It is true that humans show a deficiency in vasopressin minutes after significant hemorrhage that can respond to administration of exogenous vasopressin. When given in physiological dosing regimens, vasopressin appears to be a safe adjunct to other therapy. Definite recommendations regarding indications for use, recommended dose, and long-term outcome in patients with hemorrhagic shock await a much needed prospective, randomized, controlled trial.

AB - Trauma with resultant hypovolemic shock remains both prevalent and difficult to treat. Standard strategies using volume resuscitation and catecholamine support have historically yielded poor results. Vasopressin has emerged as a possible pharmacologic adjunct, particularly in patients with shock refractory to the administration of fluids and catecholamines. Much of the data regarding vasopressin is extrapolated from its usefulness in cases of nonhypovolemic human shock, which are supported by convincing animal studies. It is true that humans show a deficiency in vasopressin minutes after significant hemorrhage that can respond to administration of exogenous vasopressin. When given in physiological dosing regimens, vasopressin appears to be a safe adjunct to other therapy. Definite recommendations regarding indications for use, recommended dose, and long-term outcome in patients with hemorrhagic shock await a much needed prospective, randomized, controlled trial.

UR - http://www.scopus.com/inward/record.url?scp=73449102190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73449102190&partnerID=8YFLogxK

M3 - Article

VL - 75

SP - 1207

EP - 1212

JO - American Surgeon

JF - American Surgeon

SN - 0003-1348

IS - 12

ER -